Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 8/20 | 0.52 |
| ▸ | CYSLTR1 | Q9Y271 | 8/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.51 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.45 |
| ▸ | CTRC | Q99895 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9318284 | 0.94 | PTGS2 (0.54) | CYSLTR2CYSLTR1PTGS2PLA2G4BCTRC | |
| SCHEMBL9318912 | 0.93 | PTGS2 (0.59) | CYSLTR2CYSLTR1PTGS2PLA2G4BCTRC | |
| SCHEMBL30639267 | 0.82 | CTRC (0.54) | CTRCPTGESALOX5PPARG | |
| SCHEMBL9318966 | 0.81 | CTRC (0.43) | CYSLTR2CYSLTR1PTGS2CTRCPTGES | |
| SCHEMBL9318310 | 0.80 | CYSLTR2 (0.51) | CYSLTR2CYSLTR1PLA2G4BCTRCPTGES | |
| SCHEMBL9318525 | 0.80 | CTRC (0.46) | CYSLTR2CYSLTR1PLA2G4BCTRCPTGES | |
| SCHEMBL9319017 | 0.80 | CTRC (0.42) | CYSLTR2CYSLTR1PTGS2CTRCPTGES | |
| SCHEMBL568454 | 0.77 | CTRC (0.50) | CTRCPTGESALOX5PPARG | |
| SCHEMBL11521450 | 0.77 | KMT2A (0.53) | CTRCPTGESALOX5PPARG | |
| SCHEMBL14565994 | 0.77 | CTRC (0.50) | CTRCPTGESALOX5PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0576603-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO. INC. (US) | 1994-01-05 | — | — | EP | disclosed |